Delivering on commitments announced in 2020, BMS donates funds to 56 nonprofits serving medically underserved populations across the U.S. Bristol Myers Squibb today announced it has donated a total of $11 million to 56 nonprofit organizations focused on advancing health equity in the United States. These organizations will deliver programs to improve access to high-quality care as well as increase disease awareness ...

Delivering on commitments announced in 2020, BMS donates funds to 56 nonprofits serving medically underserved populations across the U.S.

Bristol Myers Squibb (NYSE: BMY) today announced it has donated a total of $11 million to 56 nonprofit organizations focused on advancing health equity in the United States. These organizations will deliver programs to improve access to high-quality care as well as increase disease awareness and education in racially and ethnically diverse and medically underserved communities, and to improve diversity in clinical research.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210224005284/en/

BMS Commitment To Advance Health Equity (Graphic: Business Wire)

BMS Commitment To Advance Health Equity (Graphic: Business Wire)

The donations, awarded in response to a special request for proposals, leverage $11 million of the $150 million pledged by the company in August 2020 to advance diversity, inclusion and health equity.

"We are realizing our vision to transform patients' lives through science as we build upon our company's strong foundation of addressing global health disparities to become one of the world's most inclusive biopharma companies," said Adam Lenkowsky, Senior Vice President, General Manager of U.S. Commercial at Bristol Myers Squibb. "We understand that the need has never been more urgent, and we have made it a priority to focus our capabilities and resources to eliminate the barriers to accessing high-quality care that exist for underserved and vulnerable populations."

He added, "In line with this priority, we have chosen organizations that have demonstrated a track record of innovative and effective work in health equity and strong ties to patients and communities. Individually, each is directing its expertise to address the root causes of inequities and to create sustainable solutions. Collectively, this funding initiative will effect change within the health care ecosystem to positively impact the equitable delivery of quality healthcare."

The grant recipients include U.S.-based patient advocacy and community-based organizations, health equity coalitions, medical societies, nonprofit healthcare institutions and others to fuel their health equity initiatives that support diverse populations including Black/African Americans, Latinx/Hispanic Americans, Asians, American Indian/Alaska Natives, Women, LGBTQ+, people with disabilities and more. The full list can be viewed above.

The donations will fund development and delivery of innovative health equity programs in areas of high unmet need within therapeutic areas such as Oncology, Hematology, Immunology and Cardiovascular Disease. The organizations will track metrics, including the number of individuals served, demographics about the targeted population and others that demonstrate the positive impact of the donation. Evaluation reports will be provided every six months, and a final impact report issued at the program conclusion.

Commitment to Health Equity by Bristol Myers Squibb and the Bristol Myers Squibb Foundation

Recognizing the need to better serve and collaborate with an increasingly diverse U.S. population and underserved communities around the world, Bristol Myers Squibb and the Bristol Myers Squibb Foundation are taking concrete steps to accelerate their respective commitments to health equity and diversity and inclusion. Bristol Myers Squibb commits to providing an additional $50 million in health equity and disease awareness and education focused grants by 2025, increasing awareness of its patient support and affordability program in communities of need, and spending $1 billion with diverse suppliers by 2025. The Bristol Myers Squibb Foundation, an independent nonprofit organization, commits to delivering a new clinical trial career development program for 250 new clinical investigators who are racially and ethnically diverse or who are committed to serving diverse and medically underserved communities, and to mentoring 250 racially and ethnically diverse medical school students to build a career pipeline with the goal of increasing diversity of participants in clinical research.

For more information on the Bristol Myers Squibb and Bristol Myers Squibb Foundation commitments to health equity and diversity and inclusion, visit BMS.com .

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn , Twitter , YouTube , Facebook , and Instagram .

corporatefinancial_news

Bristol Myers Squibb
Media:
media@bms.com

News Provided by Business Wire via QuoteMedia

AbbVie Submits Application for Risankizumab in Moderate to Severe Crohn's Disease to European Medicines Agency

ABBVie (NYSE:ABBV) today announced it has submitted an application to the European Medicines Agency (EMA) seeking approval for risankizumab (SKYRIZI ® 600 mg intravenous (IV) induction and 360 mg subcutaneous (SC) maintenance therapy), an interleukin-23 (IL-23) inhibitor, for the treatment of patients 16 years and older with moderate to severe active Crohn's disease who have had inadequate response, lost response or were intolerant to conventional or biologic therapy. The submission is supported by three pivotal Phase 3 studies, ADVANCE, MOTIVATE and FORTIFY. 1,2

"Patients with moderate to severe Crohn's disease live with challenging symptoms, such as persistent diarrhea and abdominal pain, impacting their quality of life," said Tom Hudson, senior vice president of research and development, chief scientific officer, AbbVie. "We look forward to working with the regulatory authorities and hope to offer risankizumab as a potential first-in-class treatment option for patients living with this disease."

Keep reading... Show less

SHAREHOLDER ALERT: CLAIMSFILER REMINDS BMY, OWLT, PTON, ZG INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits

ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits:

Bristol-Myers Squibb Company (BMY)
Class: Investors who received Contingent Value Rights ("CVRs") (BMY.RT) in exchange for their shares of Celgene Corporation (CELG) pursuant to Bristol-Myers' acquisition of Celgene on November 20, 2019
Lead Plaintiff Motion Deadline: December 6, 2021
MISLEADING PROSPECTUS
To learn more, visit https://claimsfiler.com/cases/nyse-bmy-3/

Keep reading... Show less
Naturally Splendid Reports Third Quarter Results for 2021

Naturally Splendid Reports Third Quarter Results for 2021

Naturally Splendid Enterprises Ltd. ("Naturally Splendid", "NSE" or "the Company") (FSE:50N)(TSXV:NSP)(OTC PINK:NSPDF) announces its unaudited financial results for the nine months ended September 30, 2021. All amounts are in Canadian dollars and are prepared in accordance with International Financial Reporting Standards

Naturally Splendid CEO Mr. Craig Goodwin reports, "The Company continues to execute on our strategic plan developing, manufacturing and distributing plant-based, meat alternative entrees. Having identified plant-based entrees as our priority, work has already begun retrofitting our existing food manufacturing facility located in British Columbia. This includes installation of a state-of-the-art packaging line which has already been initiated. This line is expected to be operational in the next 30 - 45 days. Once fully operational, this new packaging line creates significant opportunities in the retail market by providing a wide range of packaging formats that can then be placed in both chiller and freezer sections of grocery stores. The versatility of this packaging line creates opportunities for sales in multiple formats for different placement in stores across a wide range of potential clients, ultimately resulting in increased sales.

Keep reading... Show less

Amgen Named To Dow Jones Sustainability World Index For Eighth Consecutive Year

Amgen (NASDAQ:AMGN) today announced that it has been named to the Dow Jones Sustainability World Index for the eighth consecutive year, reflecting the company's enduring commitment to environmental, social, and governance (ESG) issues. Amgen also was named to the DJSI North America Index for the ninth straight year.

The DJSI Indices are among the best indicators of a company's ESG performance due to the breadth of companies evaluated – nearly 11,000 this year – and the rigorous nature of the annual assessment process. The DJSI World Index recognizes the top 10% of companies in the S&P Global Broad Market Index for performance on ESG issues, which S&P Global considers critical to generating long-term stakeholder value.

Keep reading... Show less

Gilead's Bold Ambition of Transforming Triple-Negative Breast Cancer Treatment to Be Highlighted With New Data at SABCS

ASCENT Subgroup Analysis Provides Insights on Treatment Outcomes for Black Patients with Metastatic TNBC –

Separate ASCENT Post Hoc Analysis Examines Outcomes in Patients Who Discontinue Treatment Due to Progressive Disease

Keep reading... Show less

Aptose to Hold Corporate Update Monday, December 13th

HM43239 clinical update in AML after oral presentation at 2021 ASH Annual Meeting
Luxeptinib clinical update in AML and B-cell cancers

Aptose Biosciences Inc. ("Aptose") (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that the company management team will provide a corporate update on Monday, December 13, 2021 at 5:30 PM ET, in conjunction with participation at the 2021 ASH Annual Meeting. The event will include a review of HM43239 data highlighted in an oral presentation at ASH, as well as the up-to-date clinical status of luxeptinib. HM43239 is an oral, myeloid kinome inhibitor in an international Phase 12 trial in patients with relapsed or refractory acute myeloid leukemia (AML). Luxeptinib is an oral, dual lymphoid and myeloid kinome inhibitor in a Phase 1 ab trial in patients with relapsed or refractory B cell malignancies who have failed or are intolerant to standard therapies, and in a separate Phase 1 ab trial in patients with relapsed or refractory AML or high risk myelodysplastic syndrome (MDS)

Keep reading... Show less

Top News

Related News